{"transactions":[{"id":4627244,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-09-26T00:18:30.000Z","date":"2026-09-23","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026."}],"balance_after":4000,"derivative":{"exercise_price":57.66,"expiration_date":"2034-09-22","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001193125-26-403097","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557533/000119312526403097/ownership.xml","form_type":"4"}},{"id":4627243,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-26T00:18:30.000Z","date":"2026-09-23","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock was acquired pursuant to a grant of restricted stock units (\"RSUs\"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This RSU award vests in full, one year following September 23, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Stock Split\"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split."}],"balance_after":4277,"source":{"system":"sec-edgar","filing":"0001193125-26-403097","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557533/000119312526403097/ownership.xml","form_type":"4"}},{"id":717279,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:15:26.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":32341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":32341,"derivative":{"exercise_price":18.48,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":32341},"source":{"system":"sec-edgar","filing":"0001193125-26-294560","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557533/000119312526294560/ownership.xml","form_type":"4"}},{"id":1029890,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-10-01T23:49:25.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025."}],"balance_after":8000,"derivative":{"exercise_price":56.9,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001193125-25-227232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000119312525227232/ownership.xml","form_type":"4"}},{"id":1094362,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:43:44.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":21000,"derivative":{"exercise_price":14.47,"expiration_date":"2035-07-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-093102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557533/000095017025093102/ownership.xml","form_type":"4"}},{"id":1174577,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-09T20:26:02.000Z","date":"2025-04-07","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on the Board of Directors of the Issuer."}],"balance_after":42000,"derivative":{"exercise_price":11.78,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000950170-25-052530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557533/000095017025052530/ownership.xml","form_type":"4"}},{"id":1300921,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-01-18T01:30:39.000Z","date":"2024-09-18","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 18, 2024."}],"balance_after":120000,"derivative":{"exercise_price":1.26,"expiration_date":"2032-09-17","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-25-006880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000095017025006880/ownership.xml","form_type":"5"}},{"id":1526592,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-05-06T20:40:49.000Z","date":"2024-05-02","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":82.91,"value":414550.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on April 13, 2023."}],"balance_after":66767,"source":{"system":"sec-edgar","filing":"0001048477-24-000073","document":"wk-form4_1715028037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000073/wk-form4_1715028037.xml","form_type":"4"}},{"id":1526591,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-05-06T20:40:49.000Z","date":"2024-04-30","kind":"grant","planned":true,"acquired":true,"shares":300,"price":68.646,"value":20593.8,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":71767,"source":{"system":"sec-edgar","filing":"0001048477-24-000073","document":"wk-form4_1715028037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000073/wk-form4_1715028037.xml","form_type":"4"}},{"id":1570133,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-20T00:36:22.000Z","date":"2024-03-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":22580,"price":83.87,"value":1893784.6,"ownership":{"direct":true},"balance_after":71467,"source":{"system":"sec-edgar","filing":"0001048477-24-000036","document":"wk-form4_1710894971.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000036/wk-form4_1710894971.xml","form_type":"4"}},{"id":1589769,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-03-07T22:32:40.000Z","date":"2024-03-05","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":87.07,"value":348280.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on April 13, 2023."}],"balance_after":94047,"source":{"system":"sec-edgar","filing":"0001048477-24-000030","document":"wk-form4_1709850751.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000030/wk-form4_1709850751.xml","form_type":"4"}},{"id":1610637,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-29T22:12:37.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":6465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":98047,"source":{"system":"sec-edgar","filing":"0001048477-24-000022","document":"wk-form4_1709244737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000022/wk-form4_1709244737.xml","form_type":"4"}},{"id":1610636,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-29T22:12:37.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":9338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":91582,"source":{"system":"sec-edgar","filing":"0001048477-24-000022","document":"wk-form4_1709244737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000022/wk-form4_1709244737.xml","form_type":"4"}},{"id":1610635,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-02-29T22:12:37.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":21440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."}],"balance_after":82244,"source":{"system":"sec-edgar","filing":"0001048477-24-000022","document":"wk-form4_1709244737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000022/wk-form4_1709244737.xml","form_type":"4"}},{"id":1776476,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-09-21T00:06:32.000Z","date":"2023-09-19","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023."}],"balance_after":85000,"derivative":{"exercise_price":0.68,"expiration_date":"2031-09-18","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-23-050220","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919123050220/doc4.xml","form_type":"4"}},{"id":1776475,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T00:06:32.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":4359,"price":0.69,"value":3007.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a \"sell to cover\" transaction."}],"balance_after":34153,"source":{"system":"sec-edgar","filing":"0001209191-23-050220","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919123050220/doc4.xml","form_type":"4"}},{"id":1804179,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-08-17T19:57:26.000Z","date":"2023-08-16","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":90,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on April 13, 2023."}],"balance_after":60804,"source":{"system":"sec-edgar","filing":"0001048477-23-000039","document":"wk-form4_1692302235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000039/wk-form4_1692302235.xml","form_type":"4"}},{"id":1804178,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-08-17T19:57:26.000Z","date":"2023-04-28","kind":"grant","planned":true,"acquired":true,"shares":318,"price":66.878,"value":21267.204,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":65804,"source":{"system":"sec-edgar","filing":"0001048477-23-000039","document":"wk-form4_1692302235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000039/wk-form4_1692302235.xml","form_type":"4"}},{"id":1947997,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2023-03-18T01:16:51.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":23070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter."}],"balance_after":23070,"derivative":{"exercise_price":87.74,"exercise_date":"2024-03-15","expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":23070},"source":{"system":"sec-edgar","filing":"0001567619-23-005283","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923005283/doc1.xml","form_type":"4"}},{"id":1947996,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-18T01:16:51.000Z","date":"2023-03-16","kind":"tax_withholding","acquired":false,"shares":20510,"price":93.41,"value":1915839.1,"ownership":{"direct":true},"balance_after":65486,"source":{"system":"sec-edgar","filing":"0001567619-23-005283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923005283/doc1.xml","form_type":"4"}},{"id":1947995,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-18T01:16:51.000Z","date":"2023-03-15","kind":"tax_withholding","acquired":false,"shares":3971,"price":87.74,"value":348415.54,"ownership":{"direct":true},"balance_after":85996,"source":{"system":"sec-edgar","filing":"0001567619-23-005283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923005283/doc1.xml","form_type":"4"}},{"id":1947994,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-18T01:16:51.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":10110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2023. Price not applicable."}],"balance_after":89967,"source":{"system":"sec-edgar","filing":"0001567619-23-005283","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923005283/doc1.xml","form_type":"4"}},{"id":1980551,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-02T21:09:32.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":7629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":79857,"source":{"system":"sec-edgar","filing":"0001209191-23-014609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000120919123014609/doc4.xml","form_type":"4"}},{"id":1980550,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-02T21:09:32.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":10380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":72228,"source":{"system":"sec-edgar","filing":"0001209191-23-014609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000120919123014609/doc4.xml","form_type":"4"}},{"id":1980549,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-02T21:09:32.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":20760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."}],"balance_after":61848,"source":{"system":"sec-edgar","filing":"0001209191-23-014609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000120919123014609/doc4.xml","form_type":"4"}},{"id":2043981,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2023-01-28T02:35:00.000Z","date":"2023-01-25","kind":"exercise","acquired":false,"shares":46800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects the number of options outstanding after the transactions from this specific stock option grant."}],"balance_after":0,"derivative":{"exercise_price":67.81,"exercise_date":"2013-11-15","expiration_date":"2023-05-14","underlying":"Common Stock","underlying_shares":46800},"source":{"system":"sec-edgar","filing":"0001567619-23-001396","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923001396/doc1.xml","form_type":"4"}},{"id":2043980,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2023-01-28T02:35:00.000Z","date":"2023-01-25","kind":"exercise","acquired":false,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects the number of options outstanding after the transactions from this specific stock option grant."}],"balance_after":0,"derivative":{"exercise_price":67.81,"exercise_date":"2013-11-15","expiration_date":"2023-05-14","underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001567619-23-001396","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923001396/doc1.xml","form_type":"4"}},{"id":2043979,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-28T02:35:00.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":4175,"price":116.154,"value":484942.95,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is the weighted average price. The price actually received ranged from $116.000 to $116.485. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":41088,"source":{"system":"sec-edgar","filing":"0001567619-23-001396","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923001396/doc1.xml","form_type":"4"}},{"id":2043978,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-28T02:35:00.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":44825,"price":115.654,"value":5184190.55,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is the weighted average price. The price actually received ranged from $115.000 to 115.998. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":45263,"source":{"system":"sec-edgar","filing":"0001567619-23-001396","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923001396/doc1.xml","form_type":"4"}},{"id":2043977,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-01-28T02:35:00.000Z","date":"2023-01-25","kind":"exercise","acquired":true,"shares":49000,"price":67.81,"value":3322690.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":90088,"source":{"system":"sec-edgar","filing":"0001567619-23-001396","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923001396/doc1.xml","form_type":"4"}},{"id":2124662,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-11-04T21:25:39.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":3000,"price":86.12,"value":258360.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":41088,"source":{"system":"sec-edgar","filing":"0001567619-22-019207","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922019207/doc1.xml","form_type":"4"}},{"id":2151525,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-26T23:25:35.000Z","date":"2022-09-23","kind":"sale","acquired":false,"shares":4198,"price":3.16,"value":13265.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a \"sell to cover\" transaction."}],"balance_after":38512,"source":{"system":"sec-edgar","filing":"0001209191-22-051304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919122051304/doc4.xml","form_type":"4"}},{"id":2154396,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-09-21T00:41:08.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022."}],"balance_after":20400,"derivative":{"exercise_price":3.47,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001209191-22-050808","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919122050808/doc4.xml","form_type":"4"}},{"id":2154395,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-21T00:41:08.000Z","date":"2022-09-16","kind":"grant","acquired":true,"shares":10200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock was acquired pursuant to a grant of restricted stock units (\"RSUs\"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This RSU award vests in full, one year following September 16, 2022."}],"balance_after":42710,"source":{"system":"sec-edgar","filing":"0001209191-22-050808","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919122050808/doc4.xml","form_type":"4"}},{"id":2187274,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-08-12T23:07:02.000Z","date":"2022-08-11","kind":"sale","acquired":false,"shares":3000,"price":95.62,"value":286860.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":44088,"source":{"system":"sec-edgar","filing":"0001567619-22-015887","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922015887/doc1.xml","form_type":"4"}},{"id":2240584,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-06-07T18:46:09.000Z","date":"2022-06-03","kind":"tax_withholding","acquired":false,"shares":7021,"price":77.49,"value":544057.29,"ownership":{"direct":true},"balance_after":47088,"source":{"system":"sec-edgar","filing":"0001567619-22-012432","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922012432/doc1.xml","form_type":"4"}},{"id":2251868,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-06-01T01:29:57.000Z","date":"2022-05-26","kind":"sale","acquired":false,"shares":1308,"price":78.94,"value":103253.52,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":54109,"source":{"system":"sec-edgar","filing":"0001567619-22-011966","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922011966/doc1.xml","form_type":"4"}},{"id":2251867,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-06-01T01:29:57.000Z","date":"2022-04-29","kind":"grant","acquired":true,"shares":340,"price":62.407,"value":21218.38,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":55417,"source":{"system":"sec-edgar","filing":"0001567619-22-011966","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922011966/doc1.xml","form_type":"4"}},{"id":2297176,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-14T23:54:55.000Z","date":"2022-04-13","kind":"sale","acquired":false,"shares":1180,"price":82.47,"value":97314.6,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":55077,"source":{"system":"sec-edgar","filing":"0001567619-22-008576","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922008576/doc1.xml","form_type":"4"}},{"id":2313342,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-01T01:28:18.000Z","date":"2022-03-30","kind":"sale","acquired":false,"shares":1381,"price":79.56,"value":109872.36,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":56257,"source":{"system":"sec-edgar","filing":"0001567619-22-007808","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007808/doc1.xml","form_type":"4"}},{"id":2313341,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-01T01:28:18.000Z","date":"2022-03-29","kind":"sale","acquired":false,"shares":1618,"price":79.43,"value":128517.74,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":57638,"source":{"system":"sec-edgar","filing":"0001567619-22-007808","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007808/doc1.xml","form_type":"4"}},{"id":2319093,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-25T00:49:18.000Z","date":"2022-03-23","kind":"sale","acquired":false,"shares":6129,"price":81.78,"value":501229.62,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":59256,"source":{"system":"sec-edgar","filing":"0001567619-22-007460","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007460/doc1.xml","form_type":"4"}},{"id":2319092,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-25T00:49:18.000Z","date":"2022-03-22","kind":"sale","acquired":false,"shares":2073,"price":81,"value":167913.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on February 28, 2022."}],"balance_after":65385,"source":{"system":"sec-edgar","filing":"0001567619-22-007460","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007460/doc1.xml","form_type":"4"}},{"id":2328527,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2022-03-18T01:11:22.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":28670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2023 and 1/48th on the 15th day of each month thereafter."}],"balance_after":28670,"derivative":{"exercise_price":78.27,"exercise_date":"2023-03-15","expiration_date":"2032-03-14","underlying":"Common Stock","underlying_shares":28670},"source":{"system":"sec-edgar","filing":"0001567619-22-007177","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007177/doc1.xml","form_type":"4"}},{"id":2328526,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-18T01:11:22.000Z","date":"2022-03-16","kind":"tax_withholding","acquired":false,"shares":1287,"price":80.72,"value":103886.64,"ownership":{"direct":true},"balance_after":67458,"source":{"system":"sec-edgar","filing":"0001567619-22-007177","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007177/doc1.xml","form_type":"4"}},{"id":2328525,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-18T01:11:22.000Z","date":"2022-03-15","kind":"tax_withholding","acquired":false,"shares":8418,"price":78.27,"value":658876.86,"ownership":{"direct":true},"balance_after":68745,"source":{"system":"sec-edgar","filing":"0001567619-22-007177","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007177/doc1.xml","form_type":"4"}},{"id":2328524,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-18T01:11:22.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":11940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2022. Price not applicable."}],"balance_after":77163,"source":{"system":"sec-edgar","filing":"0001567619-22-007177","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007177/doc1.xml","form_type":"4"}},{"id":2340264,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-10T22:00:45.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":9370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return for 2019 through 2021 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule:  100% vests on March 15, 2022, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."}],"balance_after":65223,"source":{"system":"sec-edgar","filing":"0001567619-22-006713","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922006713/doc1.xml","form_type":"4"}},{"id":2532982,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-28T23:48:40.000Z","date":"2021-10-26","kind":"sale","acquired":false,"shares":2739,"price":73.6,"value":201590.4,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on December 3, 2020."}],"balance_after":55853,"source":{"system":"sec-edgar","filing":"0001567619-21-018936","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921018936/doc1.xml","form_type":"4"}},{"id":2532981,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-28T23:48:40.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":342,"price":62.407,"value":21343.194,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":58592,"source":{"system":"sec-edgar","filing":"0001567619-21-018936","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921018936/doc1.xml","form_type":"4"}},{"id":2560298,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-09-24T22:12:50.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021."}],"balance_after":20400,"derivative":{"exercise_price":17.78,"expiration_date":"2029-09-21","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001209191-21-057702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919121057702/doc4.xml","form_type":"4"}},{"id":2560297,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T22:12:50.000Z","date":"2021-09-22","kind":"sale","acquired":false,"shares":3665,"price":17.78,"value":65163.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a \"sell to cover\" transaction."}],"balance_after":32510,"source":{"system":"sec-edgar","filing":"0001209191-21-057702","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919121057702/doc4.xml","form_type":"4"}},{"id":2560296,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T22:12:50.000Z","date":"2021-09-22","kind":"grant","acquired":true,"shares":10200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Common stock was acquired pursuant to a grant of restricted stock units (\"RSUs\").  Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This RSU award vests in full, one year following September 22, 2021."}],"balance_after":36175,"source":{"system":"sec-edgar","filing":"0001209191-21-057702","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919121057702/doc4.xml","form_type":"4"}},{"id":2752280,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-04-09T21:57:19.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":1537,"price":78.81,"value":121130.97,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 3, 2020."}],"balance_after":58250,"source":{"system":"sec-edgar","filing":"0001567619-21-007870","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921007870/doc1.xml","form_type":"4"}},{"id":2764830,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-04-01T18:17:01.000Z","date":"2021-03-30","kind":"sale","acquired":false,"shares":1652,"price":74.79,"value":123553.08,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 3, 2020."}],"balance_after":59787,"source":{"system":"sec-edgar","filing":"0001567619-21-007368","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921007368/doc1.xml","form_type":"4"}},{"id":2770903,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-26T21:45:41.000Z","date":"2021-03-24","kind":"sale","acquired":false,"shares":1181,"price":76.3,"value":90110.3,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 3, 2020."}],"balance_after":61439,"source":{"system":"sec-edgar","filing":"0001567619-21-007083","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921007083/doc1.xml","form_type":"4"}},{"id":2775240,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-24T00:40:21.000Z","date":"2021-03-22","kind":"tax_withholding","acquired":false,"shares":1513,"price":78.52,"value":118800.76,"ownership":{"direct":true},"balance_after":62620,"source":{"system":"sec-edgar","filing":"0001567619-21-006814","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921006814/doc1.xml","form_type":"4"}},{"id":2777885,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-20T01:01:58.000Z","date":"2021-03-18","kind":"sale","acquired":false,"shares":1308,"price":77.99,"value":102010.92,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 3, 2020."}],"balance_after":64133,"source":{"system":"sec-edgar","filing":"0001567619-21-006721","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921006721/doc1.xml","form_type":"4"}},{"id":2783467,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2021-03-18T01:27:09.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2022 and 1/48th on the 15th day of each month thereafter."}],"balance_after":26400,"derivative":{"exercise_price":78.39,"exercise_date":"2022-03-15","expiration_date":"2031-03-14","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001567619-21-006549","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921006549/doc1.xml","form_type":"4"}},{"id":2783466,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-18T01:27:09.000Z","date":"2021-03-16","kind":"tax_withholding","acquired":false,"shares":1287,"price":77.21,"value":99369.27,"ownership":{"direct":true},"balance_after":65441,"source":{"system":"sec-edgar","filing":"0001567619-21-006549","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921006549/doc1.xml","form_type":"4"}},{"id":2783465,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-18T01:27:09.000Z","date":"2021-03-15","kind":"tax_withholding","acquired":false,"shares":5273,"price":78.39,"value":413350.47,"ownership":{"direct":true},"balance_after":66728,"source":{"system":"sec-edgar","filing":"0001567619-21-006549","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921006549/doc1.xml","form_type":"4"}},{"id":2783464,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-18T01:27:09.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":10720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2021.  Price not applicable."}],"balance_after":72001,"source":{"system":"sec-edgar","filing":"0001567619-21-006549","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921006549/doc1.xml","form_type":"4"}},{"id":3006454,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-10-15T23:17:34.000Z","date":"2020-10-14","kind":"sale","acquired":false,"shares":2121,"price":79.91,"value":169489.11,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 20, 2019."}],"balance_after":61281,"source":{"system":"sec-edgar","filing":"0001567619-20-017890","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920017890/doc1.xml","form_type":"4"}},{"id":3020261,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-30T23:03:09.000Z","date":"2020-09-28","kind":"sale","acquired":false,"shares":3250,"price":17.25,"value":56062.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $17.06 to $17.65. The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer."}],"balance_after":25975,"source":{"system":"sec-edgar","filing":"0001209191-20-052511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919120052511/doc4.xml","form_type":"4"}},{"id":3022581,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-09-26T00:10:26.000Z","date":"2020-09-22","kind":"grant","acquired":true,"shares":18200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020."}],"balance_after":18200,"derivative":{"exercise_price":19.9,"expiration_date":"2028-09-21","underlying":"Common Stock","underlying_shares":18200},"source":{"system":"sec-edgar","filing":"0001209191-20-052150","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919120052150/doc4a.xml","form_type":"4/A","original_submission_date":"2020-09-24"}},{"id":3022580,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-26T00:10:26.000Z","date":"2020-09-22","kind":"grant","acquired":true,"shares":9100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This stock award was acquired pursuant to a grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This restricted stock unit award vests in full, one year following September 22, 2020."}],"balance_after":29225,"source":{"system":"sec-edgar","filing":"0001209191-20-052150","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919120052150/doc4a.xml","form_type":"4/A","original_submission_date":"2020-09-24"}},{"id":3023212,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-09-25T01:35:44.000Z","date":"2020-09-22","kind":"grant","acquired":true,"shares":18200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020."}],"balance_after":18200,"derivative":{"exercise_price":18.91,"expiration_date":"2028-09-21","underlying":"Common Stock","underlying_shares":18200},"source":{"system":"sec-edgar","filing":"0001209191-20-052039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919120052039/doc4.xml","form_type":"4"}},{"id":3023211,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-25T01:35:44.000Z","date":"2020-09-22","kind":"grant","acquired":true,"shares":9100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This stock award was acquired pursuant to a grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This restricted stock unit award vests in full, one year following September 22, 2020."}],"balance_after":29225,"source":{"system":"sec-edgar","filing":"0001209191-20-052039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919120052039/doc4.xml","form_type":"4"}},{"id":3026361,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-22T00:58:48.000Z","date":"2020-09-21","kind":"sale","acquired":false,"shares":2250,"price":19.74,"value":44415.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units."}],"balance_after":20125,"source":{"system":"sec-edgar","filing":"0001209191-20-051388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919120051388/doc4.xml","form_type":"4"}},{"id":3102167,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2020-06-23T23:24:57.000Z","date":"2020-06-19","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on December 20, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the number of options outstanding after the transactions from this specific stock option grant."}],"balance_after":15700,"derivative":{"exercise_price":63.1,"exercise_date":"2014-12-04","expiration_date":"2024-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-012520","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920012520/doc1.xml","form_type":"4"}},{"id":3102166,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-06-23T23:24:57.000Z","date":"2020-06-19","kind":"sale","acquired":false,"shares":15000,"price":124,"value":1860000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on December 20, 2019."}],"balance_after":63402,"source":{"system":"sec-edgar","filing":"0001567619-20-012520","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920012520/doc1.xml","form_type":"4"}},{"id":3102165,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-06-23T23:24:57.000Z","date":"2020-06-19","kind":"exercise","acquired":true,"shares":15000,"price":63.1,"value":946500.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Trade made pursuant to a 10b5-1 plan executed on December 20, 2019."}],"balance_after":78402,"source":{"system":"sec-edgar","filing":"0001567619-20-012520","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920012520/doc1.xml","form_type":"4"}},{"id":3102164,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-06-23T23:24:57.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":338,"price":62.586,"value":21154.068,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":63402,"source":{"system":"sec-edgar","filing":"0001567619-20-012520","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920012520/doc1.xml","form_type":"4"}},{"id":3179169,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-09T23:58:37.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":2407,"price":79.98,"value":192511.86,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 20, 2019."}],"balance_after":63064,"source":{"system":"sec-edgar","filing":"0001567619-20-007786","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920007786/doc1.xml","form_type":"4"}},{"id":3187125,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-04-03T00:39:59.000Z","date":"2020-04-01","kind":"sale","acquired":false,"shares":1537,"price":82,"value":126034.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 20, 2019."}],"balance_after":65471,"source":{"system":"sec-edgar","filing":"0001567619-20-007469","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920007469/doc1.xml","form_type":"4"}},{"id":3194583,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-27T00:34:04.000Z","date":"2020-03-25","kind":"sale","acquired":false,"shares":1618,"price":78.47,"value":126964.46,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 20, 2019."}],"balance_after":67008,"source":{"system":"sec-edgar","filing":"0001567619-20-007062","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920007062/doc1.xml","form_type":"4"}},{"id":3194582,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-27T00:34:04.000Z","date":"2020-03-24","kind":"sale","acquired":false,"shares":2041,"price":74.36,"value":151768.76,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on December 20, 2019."}],"balance_after":68626,"source":{"system":"sec-edgar","filing":"0001567619-20-007062","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920007062/doc1.xml","form_type":"4"}},{"id":3196810,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-25T00:37:23.000Z","date":"2020-03-20","kind":"tax_withholding","acquired":false,"shares":3599,"price":73.05,"value":262906.95,"ownership":{"direct":true},"balance_after":70667,"source":{"system":"sec-edgar","filing":"0001567619-20-006964","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920006964/doc1.xml","form_type":"4"}},{"id":3206280,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2020-03-18T01:05:07.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":29590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Option grant vests 12/48th on March 16, 2021 and 1/48th on the 16th day of each month thereafter."}],"balance_after":29590,"derivative":{"exercise_price":73.82,"exercise_date":"2021-03-16","expiration_date":"2030-03-15","underlying":"Common Stock","underlying_shares":29590},"source":{"system":"sec-edgar","filing":"0001567619-20-006626","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920006626/doc1.xml","form_type":"4"}},{"id":3206279,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-18T01:05:07.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":10380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 16, 2020. Price not applicable."}],"balance_after":74266,"source":{"system":"sec-edgar","filing":"0001567619-20-006626","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920006626/doc1.xml","form_type":"4"}},{"id":3206278,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-18T01:05:07.000Z","date":"2020-03-13","kind":"tax_withholding","acquired":false,"shares":7644,"price":84.5,"value":645918.0,"ownership":{"direct":true},"balance_after":63886,"source":{"system":"sec-edgar","filing":"0001567619-20-006626","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920006626/doc1.xml","form_type":"4"}},{"id":3228467,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-05T02:38:54.000Z","date":"2020-03-03","kind":"grant","acquired":true,"shares":9586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2019 as set forth in the Issuer's audited financial statements."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2020, 2021 and 2022, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On June 7, 2019, the reporting person filed a Form 4 which inadvertently over reported the total amount of securities beneficially owned by the reporting person by 50 shares.  This Form 4 corrects such error by decreasing the total amount of securities beneficially owned by the reporting person by such 50 shares."}],"balance_after":71530,"source":{"system":"sec-edgar","filing":"0001567619-20-005673","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920005673/doc1.xml","form_type":"4"}},{"id":3403655,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-01T23:16:37.000Z","date":"2019-09-30","kind":"sale","acquired":false,"shares":2375,"price":18.06,"value":42892.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":22375,"source":{"system":"sec-edgar","filing":"0001209191-19-051407","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919119051407/doc4.xml","form_type":"4"}},{"id":3405453,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-09-27T22:09:25.000Z","date":"2019-09-25","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2019."}],"balance_after":13000,"derivative":{"exercise_price":18.8,"expiration_date":"2027-09-24","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-19-051041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919119051041/doc4.xml","form_type":"4"}},{"id":3405452,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-27T22:09:25.000Z","date":"2019-09-25","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This stock award was acquired pursuant to a grant of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"This restricted stock unit award vests in full, one year following September 25, 2019."}],"balance_after":24750,"source":{"system":"sec-edgar","filing":"0001209191-19-051041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919119051041/doc4.xml","form_type":"4"}},{"id":3407319,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-24T22:07:06.000Z","date":"2019-09-20","kind":"sale","acquired":false,"shares":2250,"price":20.24,"value":45540.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units."}],"balance_after":18250,"source":{"system":"sec-edgar","filing":"0001209191-19-050587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000120919119050587/doc4.xml","form_type":"4"}},{"id":3497530,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-06-07T23:08:04.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":309,"price":68.782,"value":21253.638,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":61994,"source":{"system":"sec-edgar","filing":"0001567619-19-013104","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919013104/doc1.xml","form_type":"4"}},{"id":3499225,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-06-06T21:07:58.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":14160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 5, 2019. Price not applicable."}],"balance_after":61635,"source":{"system":"sec-edgar","filing":"0001567619-19-012953","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919012953/doc1.xml","form_type":"4"}},{"id":3577310,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-27T21:59:53.000Z","date":"2019-03-26","kind":"sale","acquired":false,"shares":3656,"price":89.1753,"value":326024.8968,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 10, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is the weighted average price. The price actually received ranged from $88.73 to $89.68. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":47475,"source":{"system":"sec-edgar","filing":"0001567619-19-007734","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007734/doc1.xml","form_type":"4"}},{"id":3578958,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-27T00:51:13.000Z","date":"2019-03-22","kind":"tax_withholding","acquired":false,"shares":3598,"price":88.05,"value":316803.9,"ownership":{"direct":true},"balance_after":51131,"source":{"system":"sec-edgar","filing":"0001567619-19-007692","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007692/doc1.xml","form_type":"4"}},{"id":3580052,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-25T21:18:39.000Z","date":"2019-03-21","kind":"sale","acquired":false,"shares":1930,"price":90.4737,"value":174614.241,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 10, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is the weighted average price. The price actually received ranged from $90.11 to $90.80. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":54729,"source":{"system":"sec-edgar","filing":"0001567619-19-007573","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007573/doc1.xml","form_type":"4"}},{"id":3580051,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-25T21:18:39.000Z","date":"2019-03-21","kind":"sale","acquired":false,"shares":2589,"price":89.6175,"value":232019.7075,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 10, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is the weighted average price. The price actually received ranged from $89.09 to $90.08. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":56659,"source":{"system":"sec-edgar","filing":"0001567619-19-007573","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007573/doc1.xml","form_type":"4"}},{"id":3583544,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-21T21:00:13.000Z","date":"2019-03-19","kind":"sale","acquired":false,"shares":3728,"price":93.07,"value":346964.96,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 10, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is the weighted average price. The price actually received ranged from $92.87 to $93.41. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":59248,"source":{"system":"sec-edgar","filing":"0001567619-19-007383","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007383/doc1.xml","form_type":"4"}},{"id":3588330,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2019-03-19T22:41:43.000Z","date":"2019-03-15","kind":"grant","acquired":true,"shares":23450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter."}],"balance_after":23450,"derivative":{"exercise_price":94.53,"exercise_date":"2020-03-15","expiration_date":"2029-03-14","underlying":"Common Stock","underlying_shares":23450},"source":{"system":"sec-edgar","filing":"0001567619-19-007243","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007243/doc1.xml","form_type":"4"}},{"id":3588329,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-19T22:41:43.000Z","date":"2019-03-15","kind":"grant","acquired":true,"shares":9370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2019. Price not applicable."}],"balance_after":62976,"source":{"system":"sec-edgar","filing":"0001567619-19-007243","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007243/doc1.xml","form_type":"4"}},{"id":3588328,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-19T22:41:43.000Z","date":"2019-03-15","kind":"tax_withholding","acquired":false,"shares":7169,"price":94.53,"value":677685.57,"ownership":{"direct":true},"balance_after":53606,"source":{"system":"sec-edgar","filing":"0001567619-19-007243","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007243/doc1.xml","form_type":"4"}},{"id":3614618,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-06T00:37:26.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":917,"price":94.76,"value":86894.92,"ownership":{"direct":true},"balance_after":60775,"source":{"system":"sec-edgar","filing":"0001567619-19-006234","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919006234/doc1.xml","form_type":"4"}},{"id":3614617,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-06T00:37:26.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":12557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."}],"balance_after":61692,"source":{"system":"sec-edgar","filing":"0001567619-19-006234","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919006234/doc1.xml","form_type":"4"}},{"id":3761777,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2018-11-17T00:14:57.000Z","date":"2018-11-14","kind":"exercise","acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 10, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Reflects the number of options outstanding after the transactions from this specific stock option grant."}],"balance_after":30700,"derivative":{"exercise_price":63.1,"exercise_date":"2014-12-04","expiration_date":"2024-06-03","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001567619-18-006564","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761918006564/doc1.xml","form_type":"4"}},{"id":3761776,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":32659,"kind":"person","name":"Ajer Jeffrey Robert","position":1,"cik":"0001557533","reported_name":"Ajer Jeffrey Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:14:57.000Z","date":"2018-11-14","kind":"sale","acquired":false,"shares":600,"price":94.3516,"value":56610.96,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 10, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in column 4 is the weighted average price.  The price actually received ranged from $94.13 to $94.66.  The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":49135,"source":{"system":"sec-edgar","filing":"0001567619-18-006564","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761918006564/doc1.xml","form_type":"4"}}],"next_cursor":"2018-11-17T00:14:57.000000Z,3761776"}